Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 6/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.30 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12378023 | 0.79 | HSD11B1 (0.34) | HSD11B1 | |
| SCHEMBL328811 | 0.75 | HSD11B1 (0.32) | HSD11B1 | |
| SCHEMBL131063 | 0.75 | GRIN2D (0.38) | HSD11B1ALDH1A1MAPTSLC22A2SLC47A1 | |
| SCHEMBL9918346 | 0.72 | — | — | |
| SCHEMBL13126722 | 0.71 | SLC22A2 (0.32) | MAPTSLC22A2SLC47A1 | |
| SCHEMBL12308339 | 0.71 | SLC22A2 (0.32) | MAPTSLC22A2SLC47A1 | |
| SCHEMBL9920198 | 0.71 | EPHX2 (0.40) | HSD11B1SLC22A2SLC47A1 | |
| SCHEMBL16448448 | 0.71 | SLC22A2 (0.32) | MAPTSLC22A2SLC47A1 | |
| SCHEMBL13126723 | 0.71 | SLC22A2 (0.32) | MAPTSLC22A2SLC47A1 | |
| SCHEMBL25509293 | 0.71 | EPHX2 (0.40) | HSD11B1SLC22A2SLC47A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | JAK1, JAK2, JAK3 | HSD11B1 1810/4885ALDH1A1 1632/4885MAPT 4022/4885 |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | HSD11B1 1216/4885ALDH1A1 1507/4885MAPT 4399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.